CRC-403: A phase 1/2 study of bbT369, a dual targeting CAR T-cell drug product with a gene edit, in relapsed and/or refractory B-cell non-Hodgkin lymphoma (NHL). A first-in-human phase 1 study of oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results